GH Research (GHRS) Assets Average (2021 - 2026)
GH Research (GHRS) posted quarterly Assets Average of $295.1 million for Q4 2025, up 52.17% year-over-year from $193.9 million in Q4 2024, and down 4.09% quarter-over-quarter from $307.7 million in Q3 2025.
GH Research (GHRS) Assets Average (2021 - 2026) Analysis & Trends
GH Research's Assets Average history runs 5 years deep, the most recent figure standing at $295.1 million for Q4 2025.
- In Q4 2025, Assets Average rose 52.17% year-over-year to $295.1 million; the TTM figure through Dec 2025 stood at $295.1 million (up 52.17% YoY), while the FY2025 annual figure was $238.3 million, up 14.94% from the prior year.
- Assets Average for Q4 2025 stood at $295.1 million, down from $307.7 million in the prior quarter.
- The five-year high for Assets Average was $316.9 million in Q2 2025, with the low at $193.9 million in Q4 2024.
- The 5-year median for Assets Average is $254.4 million (2025), against an average of $254.5 million.
- The sharpest annual moves came in 2024 and 2025: Assets Average slipped 15.47% in 2024, then surged 52.17% in 2025.
- GH Research's Assets Average stood at $286.9 million in 2021, then decreased by 10.33% to $257.2 million in 2022, then dropped by 10.81% to $229.4 million in 2023, then declined by 15.47% to $193.9 million in 2024, then soared by 52.17% to $295.1 million in 2025.
- Business Quant data shows GHRS's Assets Average at $295.1 million in Q4 2025, $307.7 million in Q3 2025, and $316.9 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | GH Research | 2.02 Bn | 1.68 Bn | - | 330.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 330.29 Mn |
| Dec 31, 2025 | 295.13 Mn |
| Sep 30, 2025 | 307.73 Mn |
| Jun 30, 2025 | 316.94 Mn |
| Mar 31, 2025 | 254.36 Mn |
| Dec 31, 2024 | 193.94 Mn |
| Sep 30, 2024 | 203.29 Mn |
| Jun 30, 2024 | 212.28 Mn |
| Mar 31, 2024 | 221.94 Mn |
| Dec 31, 2023 | 229.43 Mn |
| Sep 30, 2023 | 236.42 Mn |
| Jun 30, 2023 | 244.77 Mn |
| Mar 31, 2023 | 251.81 Mn |
| Dec 31, 2022 | 257.24 Mn |
| Sep 30, 2022 | 263.22 Mn |
| Jun 30, 2022 | 269.93 Mn |
| Mar 31, 2022 | 280.83 Mn |
| Dec 31, 2021 | 286.87 Mn |